Similar articles for PMID: 25838395

Year	Number of Results
2006	1
2007	1
2008	1
2009	5
2010	6
2011	16
2012	17
2013	8
2014	11
2015	12
2016	14
2017	13
2018	10
2019	4
2020	4
2021	11
2022	9
2023	2
2024	0

1

Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.

Dybdal-Hargreaves NF, Risinger AL, Mooberry SL. Dybdal-Hargreaves NF, et al. Clin Cancer Res. 2015 Jun 1;21(11):2445-52. doi: 10.1158/1078-0432.CCR-14-3252. Epub 2015 Apr 2. Clin Cancer Res. 2015. PMID: 25838395 Free PMC article. Review.

2

Multiple modes of action of eribulin mesylate: Emerging data and clinical implications.

Cortes J, Schöffski P, Littlefield BA. Cortes J, et al. Cancer Treat Rev. 2018 Nov;70:190-198. doi: 10.1016/j.ctrv.2018.08.008. Epub 2018 Aug 21. Cancer Treat Rev. 2018. PMID: 30243063 Free article. Review.

3

Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.

McBride A, Butler SK. McBride A, et al. Am J Health Syst Pharm. 2012 May 1;69(9):745-55. doi: 10.2146/ajhp110237. Am J Health Syst Pharm. 2012. PMID: 22517020 Review.

4

Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy.

Pivot X, Marmé F, Koenigsberg R, Guo M, Berrak E, Wolfer A. Pivot X, et al. Ann Oncol. 2016 Aug;27(8):1525-31. doi: 10.1093/annonc/mdw203. Epub 2016 May 13. Ann Oncol. 2016. PMID: 27177860 Free PMC article.

5

Clinical efficacy of eribulin mesylate for the treatment of metastatic soft tissue sarcoma.

Emambux S, Italiano A. Emambux S, et al. Expert Opin Pharmacother. 2017 Jun;18(8):819-824. doi: 10.1080/14656566.2017.1326908. Expert Opin Pharmacother. 2017. PMID: 28468516 Review.

6

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, Wright J, Tan AR, Dacosta NA, Chuang E, Smith J, O'Shaughnessy J, Shuster DE, Meneses NL, Chandrawansa K, Fang F, Cole PE, Ashworth S, Blum JL. Vahdat LT, et al. J Clin Oncol. 2009 Jun 20;27(18):2954-61. doi: 10.1200/JCO.2008.17.7618. Epub 2009 Apr 6. J Clin Oncol. 2009. PMID: 19349550 Clinical Trial.

7

Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review.

Polastro L, Aftimos PG, Awada A. Polastro L, et al. Expert Rev Anticancer Ther. 2014 Jun;14(6):649-65. doi: 10.1586/14737140.2014.920693. Expert Rev Anticancer Ther. 2014. PMID: 24852360 Review.

8

Mesenchymal-epithelial Transition and Tumor Vascular Remodeling in Eribulin Chemotherapy for Breast Cancer.

Kashiwagi S, Asano Y, Goto W, Takada K, Takahashi K, Hatano T, Tanaka S, Takashima T, Tomita S, Motomura H, Ohsawa M, Hirakawa K, Ohira M. Kashiwagi S, et al. Anticancer Res. 2018 Jan;38(1):401-410. doi: 10.21873/anticanres.12236. Anticancer Res. 2018. PMID: 29277801

9

Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.

Scarpace SL. Scarpace SL. Clin Ther. 2012 Jul;34(7):1467-73. doi: 10.1016/j.clinthera.2012.06.003. Epub 2012 Jun 25. Clin Ther. 2012. PMID: 22739019 Review.

10

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.

Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roché H, Bachelot T, Awada A, Paridaens R, Goncalves A, Shuster DE, Wanders J, Fang F, Gurnani R, Richmond E, Cole PE, Ashworth S, Allison MA. Cortes J, et al. J Clin Oncol. 2010 Sep 1;28(25):3922-8. doi: 10.1200/JCO.2009.25.8467. Epub 2010 Aug 2. J Clin Oncol. 2010. PMID: 20679609 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

132 results

Results by year